10x Genomics, Inc. Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. 10x Genomics, Inc. is a life sciences technology company providing integrated solutions (instruments, consumables, and software) for analyzing biological systems at single-cell resolution. The company operates globally with headquarters in Pleasanton, California.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $153.1 million | $146.8 million | $294.1 million | $281.1 million |
| Gross Profit | $104.2 million | $99.6 million | $197.1 million | $198.0 million |
| Gross Margin | 68% | 68% | 67% | 70% |
| Net Loss | $(37.9) million | $(62.4) million | $(97.8) million | $(113.2) million |
| Net Loss Per Share | $(0.32) | $(0.53) | $(0.82) | $(0.97) |
| Cash & Marketable Securities | $380.1 million (as of June 30, 2024) | |||
| Operating Cash Flow (YTD) | $(8.2) million | $(15.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Q2 revenue increased 4% year-over-year, driven by a 150% surge in Spatial consumables revenue ($29.3M vs. $11.7M). This growth offset a 32% decline in Chromium instrument revenue and a 7% decline in Chromium consumables.
- Expense Reduction: Total operating expenses decreased 10% in Q2 and 4% YTD. Research and Development (R&D) expenses fell 12% QoQ, and Selling, General, and Administrative (SG&A) expenses fell 9% QoQ, largely due to reduced personnel costs and lower stock-based compensation.
- Profitability Improvement: Net loss narrowed significantly in Q2 ($37.9M) compared to the prior year ($62.4M), reflecting improved cost management and higher interest income ($4.7M vs. $4.1M).
- Margin Pressure: YTD gross margin decreased 3 percentage points to 67%, attributed to product mix shifts and higher royalty obligations.
Outlook, Risks, and Contingencies
- Liquidity: Management believes existing cash and cash equivalents ($380.1M) are sufficient to meet needs for at least the next 12 months. Capital expenditures are expected to range between $15M and $20M over the next year.
- Legal Proceedings (NanoString): A jury awarded 10x Genomics over $31 million in damages against NanoString for patent infringement. However, NanoString filed for Chapter 11 bankruptcy in February 2024, and its assets were acquired by Bruker Corporation. Due to collection uncertainties, 10x has not recorded a receivable. Post-trial motions are pending.
- Legal Proceedings (Vizgen & Others): Ongoing litigation with Vizgen (trial scheduled for Feb 2025), Parse Biosciences (trial Dec 2024), and Curio Bioscience (trial May 2026) involves significant patent disputes and counterclaims regarding antitrust and unfair competition.
- Impairment Charges: The company recorded $2.1 million in impairment charges related to computer equipment and software due to the discontinuation of a productivity engineering project.
Investor Verification Checklist
- Verify the collectability of the $31 million jury award against NanoString given the bankruptcy and asset acquisition by Bruker.
- Monitor the trajectory of Spatial consumables revenue to determine if the 150% growth rate is sustainable or a one-time anomaly.
- Assess the impact of ongoing litigation costs on future SG&A expenses, as management expects legal costs to increase in the remaining quarters of 2024.
- Review the product mix shift from Chromium to Spatial instruments and its long-term effect on gross margins.
- Confirm the status of the German patent injunctions against NanoString and Curio following recent court rulings and appeals.